Evidence map›Paper›PMID 41547907›Full record

ArticleScientific reports2026

IRF7 is a novel prognostic biomarker in kidney renal clear cell carcinoma.

Shuangshuang Fu, Wenhui Zhou, Wei Yin, Ying Chen, Liyuan Cao, Yusa Chen, Zheng Xiao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shuangshuang FuDepartment of Nephrology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, No. 61 Jiefang West Rd, Changsha, 410005, Hunan, China.
Wenhui ZhouDepartment of Nephrology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, No. 61 Jiefang West Rd, Changsha, 410005, Hunan, China.
Wei YinDepartment of Nephrology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, No. 61 Jiefang West Rd, Changsha, 410005, Hunan, China.
Ying ChenDepartment of Nephrology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, No. 61 Jiefang West Rd, Changsha, 410005, Hunan, China.
Liyuan CaoDepartment of Nephrology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, No. 61 Jiefang West Rd, Changsha, 410005, Hunan, China.
Yusa Chen *Department of Nephrology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, No. 61 Jiefang West Rd, Changsha, 410005, Hunan, China. lightblue117@126.com.
Zheng Xiao *Department of Nephrology, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, No. 61 Jiefang West Rd, Changsha, 410005, Hunan, China. xzwj2021@hunnu.edu.cn.

Funding

the Excellent Youth Fund Project of the Hunan Provincial Education Department 22B0061the Youth Project of the National Natural Science Foundation of China 81800679 and 82200775the Youth Project of the Natural Science Foundation of Hunan Province 2022JJ40217, 2022JJ40228
6 · The paper itself

Abstract

Interferon regulatory factor 7 (IRF7) regulates immune responses but its prognostic role in kidney renal clear cell carcinoma (KIRC) is undefined. Given KIRC's high incidence (70-80% of renal cancers) and limited late-stage therapies, we assessed IRF7's clinical utility through multi-omics analysis. Using TCGA, GTEx, CPTAC, and tissue microarrays, we analyzed IRF7 in 33 cancers. Assessments included survival (DSS/PFI/OS), functional enrichment (GSEA), drug sensitivity (GSCA), single-cell functional state analysis using the CancerSEA database, and prognostic nomogram construction. IRF7 was dysregulated in 22 cancers (KIRC: p < 0.001), with elevated expression correlating to poor survival (p < 0.01). It associated with immune checkpoints, epigenetic modifiers, T-cell activity, and methylation. Functional analyses implicated IRF7 in fatty acid metabolism, oxidative phosphorylation, and drug sensitivity. A KIRC-specific nomogram predicted OS with high accuracy. Tissue microarrays confirmed IRF7 overexpression in KIRC versus normal tissues (p < 0.001), linked to reduced survival. IRF7 is a novel prognostic biomarker in KIRC, influencing tumor immunity and therapy response. Its integration into clinical nomograms could guide precision immunotherapy strategies.

Indexed as

Biomarkers, TumorCarcinoma, Renal CellInterferon Regulatory Factor-7Kidney NeoplasmsGene Expression Regulation, NeoplasticHumansNomogramsPrognosisBiomarkers, TumorInterferon Regulatory Factor-7IRF7 protein, humanBiomarkerInterferon regulatory factor 7Kidney renal clear cell carcinomaPrognosis

Identifiers

PMID41547907
PMCPMC12886897

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.